Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development.
Saved in:
| Title: | Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. |
|---|---|
| Authors: | Nikolaienko O; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Eikesdal HP; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Ognedal E; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Gilje B; Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway., Lundgren S; Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Blix ES; Department of Oncology, University Hospital of North Norway, Tromsø, Norway., Espelid H; Department of Surgery, Haugesund Hospital, Haugesund, Norway., Geisler J; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Geisler S; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Janssen EAM; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, Stavanger University, Stavanger, Norway., Yndestad S; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Minsaas L; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Leirvaag B; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Lillestøl R; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Knappskog S; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway., Lønning PE; K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway. per.lonning@helse-bergen.no.; Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, N5021, Bergen, Norway. per.lonning@helse-bergen.no. |
| Source: | Genome medicine [Genome Med] 2023 Dec 06; Vol. 15 (1), pp. 104. Date of Electronic Publication: 2023 Dec 06. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101475844 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-994X (Electronic) Linking ISSN: 1756994X NLM ISO Abbreviation: Genome Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
